Blastomyces dermatitidis and Histoplasma capsulatum are dimorphic fungi that often cause self-limited respiratory infections. However, they may also cause severe disseminated disease, depending on the level of the exposure to the organism and the host immune status. In addition, patients with infections caused by these fungi may have very similar clinical presentations. Although microbiologic culture is a standard method for detecting these pathogens, their recovery may require days to weeks, and the manipulation of cultures presents a significant safety hazard to laboratory personnel. Therefore, the goal of this study was to design a rapid, real-time PCR assay to detect and differentiate B. dermatitidis and H. capsulatum from culture isolates and directly from clinical specimens. Primers and fluorescence resonance energy transfer hybridization probes were designed to target the histidine kinase and glyceraldehyde-3-phosphate dehydrogenase genes of B. dermatitidis and H. capsulatum, respectively. The analytical sensitivity of the assay was determined to be 100 copies/l for both fungi . From culture isolates, the assay demonstrated 100% specificity and 100% sensitivity  for B. dermatitidis and 100% specificity and 94% sensitivity for H. capsulatum. Detection directly from 797  clinical specimens demonstrated specificities and sensitivities of 99% and 86% for B. dermatitidis and 100% and  73% for H. capsulatum compared with the results for culture. This real-time PCR assay provides a rapid method  for the detection of B. dermatitidis and H. capsulatum from culture isolates and directly from clinical specimens.
Infections with Blastomyces dermatitidis and Histoplasma capsulatum cause a variety of clinical manifestations, ranging from self-limited, mild pulmonary illness to potentially lifethreatening, disseminated disease. Rare but serious manifestations result from hematogenous dissemination to various organ systems, including the skin, bone, heart, central nervous system, or gastrointestinal or genitourinary tract (8, 17) . Patients at risk for disseminated disease include neonates and immunosuppressed patients, including those with AIDS, hematologic malignancies, or recent transplants (8, 16, 17) . Primary infections are acquired through inhalation of microconidia, which are present in the environment. In the United States, most cases of blastomycosis and histoplasmosis occur along the Ohio and Mississippi River valleys (8, 30) . Patients with infections caused by these two fungi may have very similar clinical presentations, making identification important for patient care.
The gold standard for diagnosis of blastomycosis and histoplasmosis is isolation of the organisms in culture. Although sensitive, recovery in culture and subsequent identification may require days to weeks. The organisms can be identified after growth in culture using traditional macro-and micro-scopic morphological techniques or through the use of nucleic acid hybridization probes (AccuProbes; Gen-Probe, San Diego, CA). The hybridization probes are rapid and demonstrate good sensitivity and specificity from culture, although some cross-reactivity with uncommon fungal organisms has been reported (5, 22) . Additional diagnostic tests that can be utilized for these organisms include direct smear examination, histopathology, serology, and antigen detection, with each of these methods offering advantages and limitations depending on the stage of the illness and the status of the patient. Fungal stains (e.g., calcofluor white) offer a rapid diagnostic approach but demonstrate poor sensitivity and specificity. Serologic tests, such as complement fixation and immunodiffusion, are noninvasive but are laborious, subjective, and may show low sensitivity, especially in immunocompromised hosts (25) . Antigen detection also offers a noninvasive approach and has excellent sensitivity for detection of disseminated histoplasmosis but has been demonstrated to show cross-reactivity with antigens from closely related fungal species. Furthermore, the cross-reactivity between H. capsulatum and B. dermatitidis approaches 90% with the antigen test, and therefore, differentiation of these two fungi is not practical with this approach (18, 21a, 29) .
Molecular techniques have been established as sensitive and specific methods for the diagnosis of infectious diseases, with the added advantage of rapid turnaround time (11, 27) . Due to the limitations of conventional diagnostic methods for blastomycosis and histoplasmosis, the aim of this study was to develop and validate a real-time PCR assay for the detection and differentiation of B. dermatitidis and H. capsulatum from culture isolates and clinical specimens.
(This study was presented in part at the 109th General
Meeting of the American Society for Microbiology, Philadelphia, PA, 2009 [1] .)
MATERIALS AND METHODS
Isolates. Strains of B. dermatitidis (n ϭ 60), H. capsulatum (n ϭ 54), and other fungi (n ϭ 65) identified and archived in our laboratory between 1989 and 2009 were used for assay validation. Isolates were freshly subcultured onto inhibitory mold agar (IMA) (BBL, Sparks, MD). Culture isolates were confirmed to be B. dermatitidis and H. capsulatum using FDA-approved nucleic acid hybridization probes (AccuProbes; Gen-Probe, San Diego, CA) specific for both organisms. Culture isolates were lysed by placing a 1-l loopful of the organism into a 2.0-ml tube containing 500 l of sterilized water, 0.1-mm silica glass beads, and 2.4-mm zirconia beads (BioSpec Products, Inc., Bartlesville, OK). The tubes were heated at 95°C for 10 min and then placed on a Disruptor Genie (Scientific Industries, Bohemia, NY) for 2 min to mechanically lyse the organisms and release the nucleic acid.
Clinical specimens. Clinical specimens (n ϭ 797) were collected over a 12-month period from patients with suspected fungal infection and were analyzed immediately. These included specimens from bronchial washings (n ϭ 346), bronchoalveolar (BAL) fluid (n ϭ 212), pleural fluid (n ϭ 157), tracheal secretions (n ϭ 35), tissue (n ϭ 14), sputum (n ϭ 13), lung washes (n ϭ 6), blood (n ϭ 4), bone marrow (n ϭ 5), peritoneal fluid (n ϭ 3), and other body fluids (n ϭ 2).
Culture. Respiratory specimens were cultured by inoculating 500 l of the specimen onto an IMA plate supplemented with chloramphenicol (125 g/ml) (Remel, Inc., Lenexa, KS), a brain heart infusion (BHI) blood agar plate supplemented with chloramphenicol (50 g/ml) and gentamicin (40 g/ml) (BHI III; Remel), and a BHI agar plate supplemented with chloramphenicol (50 g/ml), gentamicin (40 g/ml), and cycloheximide (0.5 mg/ml) (BHI IV; Remel). Sterile body fluids were cultured by inoculating 500 l of the clinical specimen onto an IMA plate with chloramphenicol and a BHI III plate. Tissues were homogenized and cultured by inoculating 500 l of the specimen onto an IMA plate with chloramphenicol and a BHI III plate. Plates were incubated at 30°C and held for up to 24 days. Blood and bone marrow specimens were cultured by inoculation onto an IMA plate and a Sabouraud's dextrose agar plate (SAB) (Emmons' modification, pH 7 and 2% dextrose; Remel), followed by incubation at 30°C for 30 days. The identity of culture isolates resembling B. dermatitidis and H. capsulatum was confirmed using the AccuProbe DNA hybridization probes.
Specimen extraction (nontissue specimens). Respiratory specimens and body fluids were processed prior to extraction using proteinase K (100 l) and incubation on a Thermomixer (Eppendorf, Hauppauge, NY) at 55°C and 1,400 rpm for 15 min. The liquefied specimens were heated at 95°C and mechanically lysed using a mixture of 0.1-mm silica glass beads and 2.4-mm zirconia beads on a Disruptor Genie for 2 min. Two hundred microliters of the processed specimen was then extracted on a MagNa Pure instrument (Roche Diagnostics, Indianapolis, IN) using the total nucleic acid isolation kit (Roche). Blood and bone marrow specimens (200 l) were extracted directly on the MagNA Pure LightCycler (LC) instrument (Roche Applied Sciences, Indianapolis, IN) without any preprocessing steps. Cerebrospinal fluid (CSF) specimens were heated at 95°C for 5 min before 200-l amounts were placed into MagNA Pure sample cartridges.
Tissue extraction. Fresh tissue (ϳ0.5 cm 2 ) was processed by placing the tissue in a microcentrifuge tube containing 400 l of 1ϫ Tris-EDTA (TE), 100 l proteinase K, and 50 l 10% sodium dodecyl sulfate. The tube was vortexed briefly and then placed on a Thermomixer overnight at 55°C with a mixing speed of 500 rpm. The following day, 200 l of the digested tissue was transferred into a MagNA Pure compact tube and extracted as previously described (3).
LightCycler PCR assay. The real-time PCR assay was developed on the Light-Cycler 2.0 instrument (Roche Applied Sciences, Indianapolis, IN). Primers and fluorescence resonance energy transfer (FRET) hybridization probes were designed to target a 174-bp region of the histidine kinase (DRK-1) gene of B. dermatitidis and a 192-bp region of the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene of H. capsulatum. These targets were chosen because of their highly conserved nature within each organism and the availability of sequences within public nucleotide databases (e.g., GenBank, http://www.ncbi.nlm.nih.gov/). Primers and probes were synthesized by TIB MolBiol (primer-probe set 535) (Adelphia, NJ), and their sequences are provided in Table 1 . The acceptor probe for B. dermatitidis was labeled with red 705 dye, while the acceptor probe for H. capsulatum was labeled with red 640 dye. Labeling the acceptor probes with 2 different dyes allowed for simultaneous detection and differentiation of B. dermatitidis and H. capsulatum within a single PCR assay using two different detector channels. The PCR assay was performed using the LC FastStart DNA master hybridization probe kit (Roche Applied Sciences, Indianapolis, IN), with each reaction mixture containing 3 mM MgCl 2 , 1ϫ Roche LC FastStart mix, 0.5 M each forward primer, 0.7 M each reverse primer, and 0.3 M each labeled probe. The total volume per reaction mixture was 20 l (15 l master mix plus 5 l extracted nucleic acid). PCR amplification with real-time detection was performed using the following cycling parameters: 1 template-denaturing cycle at 95°C for 10 min, followed by 45 amplification cycles at 95°C for 10 s, 60°C for 15 s, and 72°C for 20 s. Following amplification, melting curve analysis was performed by measuring the fluorescent signal during the following cycling parameters: 95°C for 0 s, 59°C for 20 s, 45°C for 20 s with a 0.2°C/s transition, and 85°C for 0 s with a 0.2°C/s transition.
Generation of positive-control plasmids. Positive control plasmids were constructed for B. dermatitidis and H. capsulatum using the primers listed in Table  1 and American Type Culture Collection strains ATCC 28305 for B. dermatitidis and ATCC 38904 for H. capsulatum. The amplified targets were cloned into the pCR 2.1 vector using the pCR 2.1 TOPO TA cloning kit (Invitrogen Corporation, Carlsbad, CA) according to the manufacturer's instructions. The plasmid constructs were then purified using the High Pure plasmid isolation kit (Roche Applied Sciences, Indianapolis, IN). The expected size of the recombinant plasmid was confirmed with 2% agarose gel electrophoresis. Subsequent Sanger sequencing confirmed the inserts to be derived from the DRK-1 and GAPDH genes of B. dermatitidis and H. capsulatum, respectively.
Analytical sensitivity and specificity. The analytical sensitivity of the assay was determined by testing a dilution series of the B. dermatitidis and H. capsulatum control plasmids. A 10-fold dilution (10 5 copies/l serially diluted to 10 0 copies/ l) of each plasmid was performed in TE buffer, and each dilution was then tested in triplicate. The analytical sensitivity in buffer was determined to be the highest dilution whereby all three replicates were positive. The analytical sensitivity in the specimen matrix was determined by spiking at least 30 analytenegative specimens (e.g., respiratory specimens) with plasmid control at the limit of detection (LOD) and testing by PCR. The specimen matrices tested were respiratory specimens (e.g., sputum, tracheal secretions, and BAL fluid), CSF, tissue (e.g., lung), body fluids (e.g., pleural and peritoneal), and blood.
The analytical specificity was determined by performing a BLAST search of each primer, each probe, and the entire amplicon sequence using the National Center for Biotechnology Information website (http://www.ncbi.nlm.nih.gov). In addition, a panel of nucleic acid extracts from bacteria (n ϭ 83), other fungi (n ϭ 66), viruses (n ϭ 23), parasites (n ϭ 5), and human DNA (n ϭ 1) were also tested for cross-reactivity to both sets of primers and probes (see the supplemental material). Amplification and Sanger dideoxy sequencing of either 16S (bacteria) or D2 LSU (fungi) ribosomal DNA (rDNA) was utilized to confirm the presence of amplifiable nucleic acids in the specificity panel. 
Downloaded from
Spiked specimen and matrix inhibition studies. As discussed above, 797 clinical specimens were tested using the PCR assay. Due to the low number of positive clinical specimens obtained in this phase of the study, plasmid control was also spiked into various specimen matrices (60 respiratory specimens, 30 CSF specimens, 120 fresh tissue specimens, 60 body fluids, and 30 blood specimens) at the LOD to further evaluate the sensitivity of the assay in these specimen sources and to look for any potential matrix-mediated inhibition. Clinical specimens negative for B. dermatitidis and H. capsulatum by LightCycler were spiked with the plasmid control to a final concentration of ϳ100 copies/l, extracted as described above, and tested by real-time PCR. PCR inhibition alone was assessed by extracting the analyte-negative clinical specimens on the MagNa Pure LC, spiking the extract with the positive-control plasmids to a concentration of 100 copies/l, and testing by real-time PCR. Extraction and/or PCR inhibition was indicated by loss of positivity as measured by melting curve analysis.
Precision. Interassay precision was determined by spiking analyte-negative respiratory specimens with the positive-control plasmid at the LOD, extracting nucleic acid, and testing by real-time PCR on 20 different days over a period of 4 months. Precision studies were performed on 5 different LightCycler instruments and by 3 different laboratory technologists to control for interinstrument and interoperator variability. The standard deviation and percent coefficient of variation (% CV) were calculated for both the crossing point (Cp) values and the melting temperatures (T m ).
RESULTS
Analytical sensitivity and specificity. The analytical sensitivity was determined to be 100 copies/l for B. dermatitidis and H. capsulatum. The B. dermatitidis probe is read at 705 nm and demonstrates a melting peak (T m ) at 66°C Ϯ 0.36°C (mean Ϯ standard deviation [SD]), while the H. capsulatum probe is read at 640 nm and has a T m at 61°C Ϯ 0.29°C (Fig. 1) . The analytical sensitivity of the assay in all specimen matrix types tested was confirmed to be 100 copies/l (see Table 4 ). The BLAST search of the primer, probe, and target sequences for both B. dermatitidis and H. capsulatum did not yield any crossreacting sequences. In addition, testing of nucleic acids from 179 potentially cross-reacting microbes demonstrated no crossreactivity with other organisms (see the supplemental material).
Sensitivity and specificity from culture isolates. The sensitivities of the assay from culture isolates were 100% (60/60) and 94.5% (51/54) for B. dermatitidis and H. capsulatum, respectively ( Table 2 ). In order to investigate the 3 discordant H. capsulatum isolates, the D2 large ribosomal subunit and intergenic spacer (ITS) regions of the discordant isolates were sequenced, and the isolates were confirmed to be Histoplasma species using both sequencing targets. Sequencing identified one of the three discordant isolates as H. capsulatum var. farciminosum (a horse pathogen consisting of diverse clades) (15) , while the other two isolates were identified as H. capsulatum var. capsulatum. The sequencing results revealed a deletion under the RED 705 probe in the H. capsulatum var. farciminosum isolate and base pair mismatches in the region targeted by the probe in the two H. capsulatum var. capsulatum isolates.
The specificity of the assay was 100% for both organisms. All members of the specificity panel, which included Chrysosporium sp. and Sepedonium sp. (phenotypic homologues to B. dermatitidis and H. capsulatum, respectively) were negative when tested by the real-time PCR assay.
Clinical sensitivity, specificity, and inhibition. A total of 797 clinical specimens were tested concurrently by fungal culture and the real-time PCR assay to assess clinical sensitivity and specificity. The sensitivity and specificity of the B. dermatitidis PCR were 86% (12/14) and 99.4% (778/783), respectively (Table 3). The overall sensitivity and specificity of the assay for H. capsulatum were 73% (11/15) and 100% (782/782), respectively ( Table 3) .
Additional studies using analyte-negative clinical samples spiked with the B. dermatitidis plasmid control at the LOD for the assay were positive in 60/60 respiratory, 30/30 CSF, 120/120 tissue, 60/60 body fluids, and 29/30 blood specimens. The spiking studies, therefore, demonstrated a sensitivity of 100% for B. dermatitidis for all specimen types except blood, which showed a sensitivity of 96.6% (29/30 ). In addition, H. capsula- tum analyte-negative specimens spiked with plasmid control at the LOD were positive in 59/60 respiratory specimens, 30/30 CSF specimens, 120/120 tissue specimens, 60/60 body fluids, and 29/30 blood specimens. H. capsulatum spiking studies therefore demonstrated a sensitivity of 100% for all specimen types except sputum and blood, which had sensitivities of 98% (59/60) and 97% (29/30), respectively. These studies showed that the overall extraction and amplification inhibition rate was Ͻ1% (2/330) ( Table 4 ). Precision. Interassay precision was determined by testing the positive control on 20 different days. The assay was positive on each of the 20 days for both organisms. For Blastomyces, the Cp was 30.3 Ϯ 0.53 cycles (mean Ϯ SD) with a CV of 1.75%, and the average T m was 66.1 Ϯ 0.36°C (CV ϭ 0.54%). For Histoplasma, the Cp was 29.5 Ϯ 0.67 cycles (CV ϭ 2.27%) and the average T m was 61.0 Ϯ 0.29°C (CV ϭ 0.48%).
DISCUSSION
Several PCR assays have been reported previously for the detection of H. capsulatum or B. dermatitidis, but these studies used a limited number of clinical specimens (4, 6, 13, 21, 24, 26) , only culture isolates (12, 20) , or animal/environmental specimens (1a, 7, 23) . In addition, many of the previous assays utilize conventional and/or nested PCR (2, 4, 12, 21, 23) , which are laborious and more prone to contamination than real-time PCR; therefore, these methods are not optimal for routine use in clinical laboratories. To our knowledge, this is the first report of a real-time PCR for the simultaneous detection and differentiation of B. dermatitidis and H. capsulatum.
Currently, definitive identification of B. dermatitidis and H. capsulatum requires growth of the organism in culture followed by microscopic examination and/or nucleic acid hybridization probe testing to identify the organism. Culture identification requires days to weeks and represents a safety risk to laboratory staff. In addition, the hybridization probe for B. dermatitidis has been shown to demonstrate cross-reactivity with other fungi, including Paracoccidioides brasiliensis, Gymnascella hyalinospora, and Emmonsia parva (14, 22) . The PCR assay described in this report can accurately detect B. dermatitidis and H. capsulatum from culture isolates and did not show cross-reactivity with P. brasiliensis, G. hyalinospora, or E. parva (see the supplemental material). In addition, the assay can detect and differentiate B. dermatitidis and H. capsulatum directly from clinical specimens within ϳ4 h from specimen receipt.
Validation studies demonstrated that the sensitivity and specificity of the B. dermatitidis assay from culture isolates were each 100%. Similarly, the specificity of the H. capsulatum assay from culture isolates was 100% (125/125); however, the sensitivity was 94% (51/54). The three discordant H. capsulatum culture isolates were re-extracted and repeated as negative by PCR. Sequencing of both the ITS and ribosomal D2 regions identified two of these isolates as H. capsulatum var. capsulatum and one isolate as H. capsulatum var. farciminosum, which causes lymphangitis in horses and mules (19) . Sequencing of the GADPH gene of all three isolates showed either a deletion or mismatches in the complementary sequence targeted by the PCR probes (data not shown). These data underscore the possibility that a small number of Histoplasma capsulatum strains may carry variations in the region targeted by this PCR assay, so clinical laboratories using this method should follow up on highly suspect isolates testing negative by PCR with morphological and DNA probe analyses or DNA sequencing.
Compared to routine fungal culture, the sensitivity and specificity of the B. dermatitidis PCR assay directly from clinical specimens were 86% (12/14) and 99% (778/783), respectively. Among the 5 discordant B. dermatitidis specimens, three (2 tissue and 1 sputum) were PCR positive, culture negative, but yeast resembling B. dermatitidis was visualized during the direct microscopic examination, suggesting that the PCR results were likely to be true positives.
The sensitivity and specificity for detection of H. capsulatum directly from clinical specimens were 73% (11/15) and 100% (782/782), respectively. The lower overall sensitivity was due to the fact that only 33% (2/6) of culture-positive BAL fluid specimens were also positive by the PCR assay. Interestingly, 2 of the 4 patients with culture-positive, PCR-negative results from BAL fluid had another specimen source that tested positive by the Histoplasma PCR assay. The sensitivity from all other specimen types (e.g., tissue and other respiratory samples) was 100% (5/5). Therefore, the lower sensitivity of PCR in BAL fluid may reflect a low concentration of organisms in this specimen type, where the volume of saline instilled and the volume of BAL fluid obtained during the procedure can vary widely across institutions (9, 10) . Although the results of our study suggest that a negative PCR from BAL fluid does not adequately rule out the presence of H. capsulatum, a positive PCR result from BAL fluid provides the health care provider with a rapid (ϳ4 h) diagnosis of histoplasmosis (versus several a Samples were spiked with positive-control plasmid to a final concentration of 100 copies/l, which was determined to be the LOD for the assay.
b The blood anticoagulant was EDTA. on July 12, 2017 by guest http://jcm.asm.org/ weeks for routine culture) and would allow for early initiation of antifungal therapy. The real-time PCR assay described above is able to reliably identify B. dermatitidis and H. capsulatum from culture isolates and directly from clinical specimens. Specimen types suggested for this assay based on the above verification studies include respiratory specimens, fresh tissue specimens, blood, bone marrow, CSF, and body fluids. Currently, urine is not considered to be a good specimen source for this assay. Previous literature (25) and unpublished studies performed in our laboratory indicate that Histoplasma nucleic acid is not routinely found in urine of patients with disseminated histoplasmosis. Therefore, the H. capsulatum antigen assay is the recommended test for urine at this time. Although the PCR assay provides a rapid result, the data presented in this report suggest that routine culture should also be performed on all clinical specimens to enhance sensitivity.
In summary, the real-time PCR assay described in this report offers a rapid, sensitive, and specific method for the detection and differentiation of B. dermatitidis and H. capsulatum from culture isolates and clinical specimens. An additional advantage of the real-time PCR assay is increased safety for laboratory personnel by reducing the need to manipulate cultures of specimens that are positive by the PCR assay.
